Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer.

Runcie K, Bracero Y, Samouha A, Manji G, Remotti HE, Gonda TA, Saenger Y

DOI: 10.1093/oncolo/oyae200
Published: 2025 Jan 17
Container: The oncologist
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyae200,
  title = {Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer.},
  author = {Runcie K and Bracero Y and Samouha A and Manji G and Remotti HE and Gonda TA and Saenger Y},
  year = {2025},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyae200},
  url = {https://doi.org/10.1093/oncolo/oyae200}
}

RIS

TY  - JOUR
TI  - Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer.
AU  - Runcie K
AU  - Bracero Y
AU  - Samouha A
AU  - Manji G
AU  - Remotti HE
AU  - Gonda TA
AU  - Saenger Y
PY  - 2025
JO  - The oncologist
DO  - 10.1093/oncolo/oyae200
UR  - https://doi.org/10.1093/oncolo/oyae200
ER  -

APA

K, R., Y, B., A, S., G, M., HE, R., TA, G., & Y, S. (2025). Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer.. The oncologist. https://doi.org/10.1093/oncolo/oyae200

Source records

pubmed · retrieved 2026-09-26T16:08:57.444Z